Diffusion pharmaceuticals inc. (DFFN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating activities:
Net loss

-2,558

-3,752

-2,804

-2,495

-2,747

-5,570

-6,719

-2,765

-3,313

1,789

5,096

20,387

-28,638

-2,570

-5,436

-3,806

-6,223

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,422

-1,331

-1,243

-5,067

-3,449

-4,455

-1,380

-

-

-

-

-

-

-

-

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,349

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-307

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

134

9

9

9

Depreciation

27

27

18

34

18

28

26

26

28

28

27

5

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

7

2

2

1

2

-317

368

323

191

-

-

-

-

-

-

-

-

Stock-based compensation expense

191

130

145

149

91

249

327

319

324

266

292

315

366

269

390

338

393

220

141

136

95

531

783

141

149

-

-

-

-

-

-

-

-

(Gain) / loss on adjustments to fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,960

0

9,216

-236

-

-

-

-

(Gain)/loss on adjustment to fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,820

2,047

Warrants, options and stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,323

2,280

928

193

240

Common stock issued for advisory services

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

921

487

0

0

0

0

-

-

-

-

-

-

-

130

-

-

-

-

Warrant related expense, change in fair value, and other financing expenses

-

-

-

-

-

-

-

-

-

3,162

8,441

23,387

-26,015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant related expense and change in fair value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in deferred income taxes

-362

818

-225

-108

-150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

1

21

-73

28

57

31

2

1

3

5

68

34

56

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Stock issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses, deposits and other assets

346

-74

-458

-13

119

406

-220

-278

92

2

593

-31

99

-268

-33

-114

97

36

1

6

-15

-439

-78

-175

-286

-18

-30

13

36

6

-67

54

-3

Accounts payable, accrued expenses and other liabilities

-455

264

255

-202

250

-141

257

-155

-236

-167

-246

-126

-1,123

581

53

-441

797

116

230

165

135

-1,159

385

-3,347

319

-1,043

-34

1,014

194

-1,366

-58

1,151

-127

Net cash used in operating activities

-3,504

-2,438

-2,152

-2,610

-2,657

-3,027

-1,916

-2,540

-3,289

-2,282

-3,888

-2,746

-3,415

-1,414

-1,864

-2,859

-4,630

-2,265

-981

-998

-938

-1,930

-1,978

-4,688

-432

-

-

-

-

-1,497

-559

-407

-1,846

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

9

374

57

6

0

0

0

1

26

2

8

2

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of certificates of deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,500

-

-

-

-

-

-

-

-

-

-

-

-

Cash received in reverse merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

8,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

9,990

-374

-10,057

-6

0

0

-0

8,498

-26

-2

-8

2,497

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-306

-

-

-

-

Cash flows provided by financing activities:
Proceeds received from the exercise of common stock warrants

393

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of Series A convertible preferred stock and warrants, net

-

-

-

-

-

-

-

-

-

0

0

7,860

14,269

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of Series A convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-400

0

0

400

-

-

-

-

-

-

-

-

Payments on notes payable to officers and a director

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71

Payment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-200

-611

-673

-366

-1,831

Proceeds from the sale of common stock

-

-

-

-

-

-

0

0

10,846

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing costs that were previously classified in accounts payable

238

-

-

-

-

0

0

174

253

28

54

-144

187

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

155

-

-

-

-

0

0

-724

10,592

-28

-1,934

8,005

14,081

-54

1,880

0

0

-

-

-

-

76

-1,372

31,605

400

-

-

-

-

1,652

673

437

1,760

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

-

-

-

-

Decrease in cash and equivalents from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-106

-

-

-

-

Decrease in cash and equivalents from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-94

-

-

-

-

Net decrease in cash and cash equivalents

-3,349

8,037

-2,232

3,039

-2,657

-3,027

-1,916

-3,264

7,303

7,680

-6,197

-4,798

10,659

-1,468

15

-2,859

3,868

93

-984

-1,007

1,559

-1,904

-3,351

26,917

-32

-0

176

-32

-200

155

113

29

-85

Supplemental disclosure of cash flow information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Reclassification of deferred offering costs upon completion of private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series A cumulative preferred dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of subscription receivable upon sale of Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

8,280

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of deferred offering costs upon completion of private placement

-

-

-

-

-

-

-

-

-

-

-

-

180

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs in accounts payable and accrued expenses

258

-

-

51

28

-

-

-

174

-

-

-228

178

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right of use asset and current and noncurrent liability

-

0

0

0

334

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of accrued dividends related to the issuance of common stock to Series A convertible preferred stock holders

-

-

-

-

-

0

0

0

1,148

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17

231

-81

73

190

Deferred salary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

181

-72

412

624

188

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22

526

-18

178

-126

Series A cumulative preferred dividends

-

-

-

-

-

0

0

0

85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of convertible notes and related accrued interest into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

711

19,653

47

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Consideration in connection with RestorGenex Corporation merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

21,261

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of business in exchange for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

6,800

-

-

-

-

-

-

-

-

Cash paid during the period for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0